Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of bertilimumab in moderate to severe active ulcerative colitis
MOH_2017-10-31_000652Phase 2Recruiting
- Sponsor
- Immune Pharmaceuticals Inc.
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing bertilimumab with placebo (2 arms). Started Sep 2015; status: recruiting.
02
Drugs
bertilimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-10-31_000652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-31_000652.